SCHEMBL2172907

SCHEMBL2172907

C[C@]1(C(=O)N2CCN(c3ccccc3)CC2)N(C(=O)O)C[C@@H](Sc2ccccc2)C[C@]1(C)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.45
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.40
HPGD P15428 1/20 0.40
MAPT P10636 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.38
HSD11B1 P28845 1/20 0.38
TSHR P16473 4/20 0.38
POLB P06746 2/20 0.38
HTT P42858 2/20 0.38
MAPK1 P28482 2/20 0.37
ALOX15 P16050 1/20 0.37
USP2 O75604 1/20 0.37
NPSR1 Q6W5P4 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173564 0.84 LMNA (0.49) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2173178 0.84 LMNA (0.49) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2173082 0.81 ALDH1A1 (0.46) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2173080 0.78 ALDH1A1 (0.44) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2177052 0.78 LMNA (0.43) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2177320 0.75 LMNA (0.41) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2174089 0.75 LMNA (0.41) LMNAALDH1A1SMN1; SMN2HPGDMAPT
SCHEMBL4476420 0.75 GPR119 (0.39) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL2176908 0.75 ALDH1A1 (0.43) LMNAALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL2174272 0.73 ALOX15 (0.41) LMNAALDH1A1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 LMNA 2321/4885ALDH1A1 673/4885SMN1; SMN2 4489/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 LMNA 2198/4885ALDH1A1 497/4885SMN1; SMN2 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.